Navigation Links
Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
Date:12/13/2010

l allow us to expedite the initiation of the Phase 3 trial, since we will no longer have to halt enrollment after 60 patients are accrued to the trial to allow the DSMB to review safety data. We will be able to complete the Phase 1 study at the same time the required 13-week animal toxicology studies are being conducted and while the Phase 3 clinical trial material is manufactured and packaged," concluded Dr. Tagliaferri.

We anticipate starting the Phase 1 study in Q1, 2011 and beginning the Phase 3A pivotal trial in Q2, 2011.

"We are excited to move Menerba forward in the path to commercialization. Menerba is an important new treatment approach for millions of women suffering from menopausal hot flashes", said Isaac Cohen, O.M.D., Chairman and CEO of Bionovo. "The discussion with the FDA was also fruitful concerning future potential labeling of Menerba. Bionovo provided additional data to support our claim that Menerba is not an estrogen and not a SERM. The FDA acknowledged that Menerba is a selective estrogen receptor beta agonist. Granted we continue to show no safety concerns after the Phase 3 trials, Menerba will provide a safer alternative to current hormone therapy."

About Menerba

Menerba is an oral botanical drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with activation of estrogen receptor alpha (ER-a) and that activation of estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. The active ingredients in Menerba are derived from botanicals with centuries of recorded safe, effective use in traditional Chinese medicine (TCM). B
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... New high priced hepatitis C drugs will increase federal ... to $5.8 billion next year, according to a new ... the Pharmaceutical Care Management Association (PCMA). Milliman projects that ... as 8.6 percent in 2015 as a result of ... The study finds that the majority of new ...
(Date:7/29/2014)... Numotion,s Board of Directors has announced that as ... the company,s new Chief Executive Officer. Swinford ... where he worked primarily for GE Healthcare Services, running businesses ... billion. His most recent position was as President and CEO ... thrilled to join Numotion," said Mike Swinford . "I ...
(Date:7/29/2014)... July 29, 2014  Roche (SIX: RO, ROG; OTCQX: ... Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by ... unique ways Roche is partnering with customers to redefine ... tell us every day that they,re looking for a ... in their labs and offices," said Jack Phillips ...
Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
(Date:7/29/2014)... 30, 2014 Dignity Sciences Limited, a ... of a Phase I trial with DS107G, an oral ... study was a randomized, placebo-controlled, double-blind, single-ascending and multiple ... pharmacokinetics and effect of food on DS107G in healthy ... profile of DGLA following both single and multiple oral ...
(Date:7/29/2014)... have discovered a chemical alteration in a single human ... larger studies, could give doctors a simple blood test ... , The discovery, described online in The American ... gene involved in the function of the brain,s response ... what might otherwise be an unremarkable reaction to the ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... program was created by a holistic nutritional and functional medicine ... way of overcoming this problem. , Karen suffered from leaky ... so much time to develop this unique treatment. , ... her method, with sufferers from all around the world. The ...
(Date:7/29/2014)... Washington, New York (PRWEB) July 29, 2014 ... to protecting the rights of victims injured by defective ... lawsuit has been filed by plaintiffs in Canada who ... risk of cardiovascular events with the low testosterone ... filed on July 22, 2014 in the Ontario Superior ...
Breaking Medicine News(10 mins):Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3
... Fla., Dec. 13 The Quantum Group,Inc. (Amex: ... it,has completed its registered public offering, raising $13.2 ... it has initiated trading,on the American Stock Exchange ... the symbol "QGP.U." In addition, Quantum common shares,formerly ...
... for the Hospital,s ... State-of-the-Art Cardiothoracic Center, SANTA CLARA, Calif., Dec. ... a new network,infrastructure to support a trust-wide Picture Archiving ... Hospitals, part,of the NHS Foundation Trust in Essex, United ...
... plan services for members, ROCKVILLE, Md., Dec. ... of comprehensive dental plans and administration, has,announced a ... the,nation,s leading integrated health plan provider. GDS will ... and,call center support to Kaiser Permanente Northwest,s 180,000 ...
... NEW YORK, Dec. 13 Getting in shape shouldn,t ... a public health,advocate and veteran of the fitness industry. ... Year, Holland has developed a novel fitness,program to help ... Ease-In Longevity program allows people to "ease into," exercise,going ...
... to 100,000-fold, study finds , , THURSDAY, Dec. 13 (HealthDay News) ... team reports that tiny fibers commonly found in semen drastically ... , According to a study in the Dec. 14 issue ... then ferry it to target cells, increasing its ability to ...
... human spine evolved differently in males and females in ... carrying a baby, according to research spearheaded at The ... are documented for the first time in the Dec. ... adaptation first appeared at least two million years ago, ...
Cached Medicine News:Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 2Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 3Health News:Extreme Networks Provides Resilient Wired and Wireless Network to the UK's Basildon & Thurrock Hospital 2Health News:Extreme Networks Provides Resilient Wired and Wireless Network to the UK's Basildon & Thurrock Hospital 3Health News:Fitness Guru Offers Novel Exercise Program and Tips to Stick with Exercise in the New Year 2Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Adapting to pregnancy played key role in human evolution, study shows 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: